ライフサイエンスコーパス: pulmonary hypertension

1 ventricular failure (chronic thromboembolic pulmonary hypertension).

2 rom the Dutch National Network for Pediatric Pulmonary Hypertension.

3 f subsets of patients with heart failure and pulmonary hypertension.

4 some of these treatments improve SCD-related pulmonary hypertension.

5 rs) underwent PEA for chronic thromboembolic pulmonary hypertension.

6 get for therapy in selected HF patients with pulmonary hypertension.

7 pg/mL; 217 of 3223 cohort members (6.7%) had pulmonary hypertension.

8 ulmonary vasoconstriction and progression of pulmonary hypertension.

9 transcription factor in the pathogenesis of pulmonary hypertension.

10 herapeutic activity in preclinical models of pulmonary hypertension.

11 gies and treatments for the various types of pulmonary hypertension.

12 y higher risk of death than patients without pulmonary hypertension.

13 ted patients who have chronic thromboembolic pulmonary hypertension.

14 signalling in disorders such as fibrosis and pulmonary hypertension.

15 ases have become the most frequent causes of pulmonary hypertension.

16 ysiological symptoms associated with hypoxic pulmonary hypertension.

17 y pressure in SCD patients with precapillary pulmonary hypertension.

18 udy of the effects of iron status on hypoxic pulmonary hypertension.

19 es in the lung, promoting the development of pulmonary hypertension.

20 ent knowledge on the use of beta-blockers in pulmonary hypertension.

21 with preserved ejection fraction (HFpEF) or pulmonary hypertension.

22 ws and humans susceptible to hypoxia-induced pulmonary hypertension.

23 nhibition of miR-143-3p blocked experimental pulmonary hypertension.

24 al access were less often women and less had pulmonary hypertension.

25 lammation of rats with monocrotaline-induced pulmonary hypertension.

26 target for the pharmacological management of pulmonary hypertension.

27 d 777 patients (514 women) with precapillary pulmonary hypertension.

28 nderlies increased vascular contractility in pulmonary hypertension.

29 safety of exercise training in patients with pulmonary hypertension.

30 contribute to distal organ hypoperfusion and pulmonary hypertension.

31 in vivo, which can instigate development of pulmonary hypertension.

32 safety of exercise training in patients with pulmonary hypertension.

33 osis, evaluation, and treatment of pediatric pulmonary hypertension.

34 tion as a potential therapeutic strategy for pulmonary hypertension.

35 r, has been used in clinical trials to treat pulmonary hypertension.

36 ter to measure in follow-up of patients with pulmonary hypertension.

37 ss syndrome, primary ciliary dyskinesia, and pulmonary hypertension.

38 ecommendations for the care of children with pulmonary hypertension.

39 utic targeting of SrcFKs in the treatment of pulmonary hypertension.

40 cesses that include both atherosclerosis and pulmonary hypertension.

41 d congenital heart disease and in those with pulmonary hypertension.

42 on the progression of monocrotaline-induced pulmonary hypertension.

43 xhibit genetic resistance to hypoxia-induced pulmonary hypertension.

44 luation of iron replacement in patients with pulmonary hypertension.

45 ality of life in patients with COPD and mild pulmonary hypertension.

46 fy Cpc-PH patients as isolated postcapillary pulmonary hypertension.

47 s to support the right ventricle function in pulmonary hypertension.

48 ute to the increased tone that characterizes pulmonary hypertension.

49 ry endarterectomy for chronic thromboembolic pulmonary hypertension.

50 y introduced as a novel treatment option for pulmonary hypertension.

51 mpared with nonsevere chronic thromboembolic pulmonary hypertension.

52 erved ejection fraction and exercise-induced pulmonary hypertension.

53 d therapies targeting the right ventricle in pulmonary hypertension.

54 onist is among the most effective agents for pulmonary hypertension.

55 for understanding the changes that occur in pulmonary hypertension.

56 ly protected against chronic hypoxia-induced pulmonary hypertension.

57 g stress echocardiography, and patients with pulmonary hypertension.

58 y important roles in the pulmonary artery in pulmonary hypertension.

59 d to elevated LV end-diastolic pressures and pulmonary hypertension.

60 isk factors in patients with newly diagnosed pulmonary hypertension.

61 C) function, acute cor pulmonale (ACP) (1C), pulmonary hypertension (1B), symptomatic pulmonary embol

62 PE + SU rats exhibited sustained pulmonary hypertension (62 +/- 13 and 53 +/- 14 mmHg at

63 This review summarizes recent advances in pulmonary hypertension, a leading cause of morbidity and

64 Chronic thromboembolic pulmonary hypertension, a rare complication of acute pul

65 ology, and emerging clinical perspectives on pulmonary hypertension across the broad spectrum of hear

66 evels were associated with increased odds of pulmonary hypertension (adjusted odds ratio per log incr

67 Pulmonary hypertension affects approximately 10% of adul

68 ticular, our findings raise the suspicion of pulmonary hypertension after IUGR.

69 inoperable CTEPH or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy (P

70 The Pulmonary Hypertension and Angiogenic Cell Therapy (PHAC

71 Pulmonary hypertension and associated right ventricular

72 inflammatory effects of sarcoidosis, such as pulmonary hypertension and bronchiectasis, might also co

73 h as abnormal angiogenesis, atherosclerosis, pulmonary hypertension and cardiac hypertrophy have been

74 Phenotyping by pulmonary hypertension and endothelin-1 level showed mor

75 medical subject headings and text words for pulmonary hypertension and health disparities.

76 ality decreasing in order from subgroup with pulmonary hypertension and high endothelin-1 (high endot

77 othelin-1 <1.7 pg/mL; lower 3 quartiles); no pulmonary hypertension and high endothelin-1; and no pul

78 gher risk of dying of chronic thromboembolic pulmonary hypertension and identifies a level of residua

79 alidation cohort with known risk factors for pulmonary hypertension and in patients with established

80 eficiency is involved in the pathogenesis of pulmonary hypertension and iron replacement is a possibl

81 endothelin-1: >/=1.7 pg/mL; upper quartile); pulmonary hypertension and low endothelin-1 <1.7 pg/mL;

82 y hypertension and high endothelin-1; and no pulmonary hypertension and low endothelin-1 (log-rank ch

83 a diameter ratio >1 (PA:A>1) is a marker for pulmonary hypertension and predicts chronic obstructive

84 In contrast, chronic hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling

85 uated both hypoxia and monocrotaline-induced pulmonary hypertension and restrained extracellular matr

86 Patients with pulmonary hypertension and right heart failure have a hi

87 set of profound hypoxemia resulting in acute pulmonary hypertension and right ventricular distension.

88 gen consumption, or VE/VCO2 in patients with pulmonary hypertension and RVD.

89 ntribute to protection against high-altitude pulmonary hypertension and supports sGC as a pharmacolog

90 onic elevation of pulmonary artery pressure (pulmonary hypertension) and right ventricular hypertroph

91 hemic heart disease, valvular heart disease, pulmonary hypertension, and congenital heart disease.

92 eders" were correlated with cardiac failure, pulmonary hypertension, and encephalomalacia at birth.

93 ease, manifested as pronounced leukocytosis, pulmonary hypertension, and even death.

94 at the horizon as arrhythmias, endocarditis, pulmonary hypertension, and heart failure, and the need

95 eptide activation, higher filling pressures, pulmonary hypertension, and increased cardiac output, de

96 Deaths relate to leukocytosis, pulmonary hypertension, and pneumonia.

97 AI was also associated with stroke, pulmonary hypertension, and priapism, and cf-PWV was ass

98 rterial hypertension, chronic thromboembolic pulmonary hypertension, and pulmonary hypertension due t

99 monary arteriopathy, reduced the severity of pulmonary hypertension, and reduced the degree of cardia

100 ients with compromised right heart function, pulmonary hypertension, and severe acute hypoxemic respi

101 tricular failure in those with postcapillary pulmonary hypertension; and hydroxyurea or transfusions

102 Exercise training in patients with pulmonary hypertension appears safe and is associated wi

103 helial cells specifically resulted in severe pulmonary hypertension ( approximately 118% increase in

104 The most common forms of pulmonary hypertension are pulmonary arterial hypertensi

105 ctors, such as severity of liver disease and pulmonary hypertension, are not included in the exceptio

106 Pulmonary hypertension associated with heart failure wit

107 , we successfully detected four well-defined pulmonary hypertension-associated biomarkers, namely, fi

108 or cells expressing PW1 and participating in pulmonary hypertension-associated vascular remodeling.

109 tion of MMC induced PVOD, as demonstrated by pulmonary hypertension at right-heart catheterization at

110 rtension, and in patients with postcapillary pulmonary hypertension because of left heart disease.

111 or of outcomes in patients with precapillary pulmonary hypertension because of pulmonary arterial hyp

112 a large cohort of patients with precapillary pulmonary hypertension before and after initiation of tr

113 tic elastase inhibitors reverse experimental pulmonary hypertension but cause hepatotoxicity in clini

114 phy, helps identify SCD patients at risk for pulmonary hypertension, but definitive diagnosis require

115 a major cause of morbidity and mortality in pulmonary hypertension, but its mechanism remains unknow

116 striction, systemic inflammation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors

117 n healthy volunteers and three patients with pulmonary hypertension by using a stimulated echo sequen

118 acyclin analog approved for the treatment of pulmonary hypertension, can be repurposed to improve hem

119 We also observed altered expression of many pulmonary hypertension-causing genes in Egln1(Tie2) lung

120 lusive disease (PVOD) is an uncommon form of pulmonary hypertension characterized by the obstruction

121 ve Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA), an ongoing European pu

122 Long-Term PAH Disease Management score, the Pulmonary Hypertension Connection equation, and the Mayo

123 9 patients with congestive heart failure and pulmonary hypertension consecutively enrolled from clini

124 d mechanisms of right ventricular failure in pulmonary hypertension could be predicted by using super

125 ostcapillary and combined pre-/postcapillary pulmonary hypertension (Cpc-PH) in left heart disease (P

126 nd combined post-capillary and pre-capillary pulmonary hypertension (Cpc-PH).

127 microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hy

128 Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, debilitating,

129 d in 34 patients with chronic thromboembolic pulmonary hypertension (CTEPH) undergoing invasive treat

130 Chronic thromboembolic pulmonary hypertension (CTEPH) was confirmed in 4 (2.1%)

131 hysiological basis of chronic thromboembolic pulmonary hypertension (CTEPH) will be accelerated by an

132 Cross-sectional analysis: presence of pulmonary hypertension (defined as an elevated pulmonary

133 Elevated tricuspid regurgitant jet velocity, pulmonary hypertension, diastolic, and autonomic dysfunc

134 a contributor to preoperative heart failure, pulmonary hypertension did not significantly influence c

135 sing system to detect multiple biomarkers of pulmonary hypertension diseases in a single device.

136 c thromboembolic pulmonary hypertension, and pulmonary hypertension due to left-sided heart and lung

137 For patients with pulmonary hypertension due to left-sided heart disease o

138 ulmonary artery in subjects with and without pulmonary hypertension during spontaneous respiration an

139 Pulmonary comorbidities include pulmonary hypertension, emphysema, and lung cancer, whil

140 (PEA) is potentially curative, but residual pulmonary hypertension following surgery is common and i

141 d severe or nonsevere chronic thromboembolic pulmonary hypertension (> 900 or </= 900 dynes.s/cm, res

142 High-altitude pulmonary hypertension (HAPH) has heritable features and

143 nt (TR) jet velocity and its relationship to pulmonary hypertension has been controversial in sickle

144 Interest in left-sided pulmonary hypertension has increased remarkably in recen

145 ation between plasma endothelin-1 levels and pulmonary hypertension has not been studied in the gener

146 oaches to caring for pediatric patients with pulmonary hypertension have been limited by the lack of

147 d from the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Centre)

148 2012, a total of 225 patients diagnosed with pulmonary hypertension in 1998 or after were collected f

149 hich decreased arteriole muscularization and pulmonary hypertension in 2 experimental animal models o

150 nversion of androgens to estrogen and blunts pulmonary hypertension in animals, but its efficacy in t

151 nic lipopolysaccharide administration caused pulmonary hypertension in Bmpr2(+/-) mice but not in wil

152 n matching in regional hypoxia, but promotes pulmonary hypertension in global hypoxia.

153 We also determined the development of pulmonary hypertension in male and female mice deficient

154 ates hypoxia-induced vascular remodeling and pulmonary hypertension in mice and suggest EP3 inhibitio

155 miRNA-96 mimic on the development of hypoxic pulmonary hypertension in mice was also assessed.

156 elastase inhibitor elafin attenuates hypoxic pulmonary hypertension in mice, but its potential to imp

157 Such VAEs include pulmonary hypertension in patients treated with dasatini

158 hophysiology, and management implications of pulmonary hypertension in patients with obstructive hype

159 induced hemodynamic and vascular changes of pulmonary hypertension in rats (n=8) and elevated interl

160 antibodies partially reversed development of pulmonary hypertension in rats and substantially reduced

161 P12 expression attenuates the development of pulmonary hypertension in rats housed in a hypoxic atmos

162 c reduced the development of hypoxia-induced pulmonary hypertension in the mouse.

163 nd that antagonism of miR-29 would attenuate pulmonary hypertension in transgenic mouse models of Bmp

164 a protective role of miR-143 in experimental pulmonary hypertension in vivo in miR-143-/- and anti-mi

165 mortality, outcomes that are associated with pulmonary hypertension, in a population cohort is unclea

166 ular remodelling, with a particular focus on pulmonary hypertension, including growth-factor receptor

167 sed pulmonary artery pressures in a model of pulmonary hypertension induced by chronic hypoxia.

168 Rats with pulmonary hypertension induced by vascular endothelial g

169 quency pulmonary artery denervation on acute pulmonary hypertension induced by vasoconstriction, and

170 ase with 2 subtypes: isolated post-capillary pulmonary hypertension (Ipc-PH) and combined post-capill

171 Pulmonary hypertension is a common hemodynamic complicat

172 Pulmonary hypertension is a complex disease that extends

173 Pulmonary hypertension is a substantial global health is

174 f the underlying disease, the development of pulmonary hypertension is associated with clinical deter

175 Pulmonary hypertension is associated with diverse cardia

176 Management of adults with sickle-related pulmonary hypertension is based on anticoagulation for t

177 patients live in developing countries, where pulmonary hypertension is frequently associated with con

178 However, its role in management of pulmonary hypertension is not well defined.

179 lmonary artery pressure in SCD patients with pulmonary hypertension is only moderately elevated, they

180 Progression of hypoxic pulmonary hypertension is thought to be due, in part, to

181 Progression of hypoxic pulmonary hypertension is thought to be due, in part, to

182 ptor blockade and hypoxia caused more severe pulmonary hypertension, judged by elevated right ventric

183 lafin reduced elastase activity and reversed pulmonary hypertension, judged by regression of right ve

184 se processes culminate in the development of pulmonary hypertension, left ventricular diastolic heart

185 lmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic ki

186 Pulmonary hypertension (mean pulmonary artery pressure,

187 %) met hemodynamic criteria for precapillary pulmonary hypertension (mean pulmonary artery pressure,

188 In a rat pulmonary hypertension model (monocrotaline), we studied

189 observations in established animal models of pulmonary hypertension (monocrotaline and SuHx).

190 scle, and kidneys, leading, respectively, to pulmonary hypertension, muscle weakness, and sodium rete

191 Patients with severe chronic thromboembolic pulmonary hypertension (n = 15) had higher EVLWPBW value

192 ntrol subjects (symptomatic patients without pulmonary hypertension, n=139).

193 cemia, septic shock, endotoxemia, persistent pulmonary hypertension, nitric oxide, extracorporeal mem

194 lure, endocarditis, during valvular surgery, pulmonary hypertension, noncardiac causes, and unknown c

195 These forms of pulmonary hypertension occur predominantly in those youn

196 use during pregnancy and risk of persistent pulmonary hypertension of the newborn (PPHN) has been co

197 s study was to assess the impact of baseline pulmonary hypertension on long-term outcomes in patients

198 f eight), pulmonary embolism (two of eight), pulmonary hypertension (one of eight), and lymphopenia (

199 t reveal significant differences in residual pulmonary hypertension or RV dysfunction.

200 ignaling, and to reverse severe experimental pulmonary hypertension or vascular pathology in the huma

201 ty for patients with advanced heart failure, pulmonary hypertension, or acute myocardial infarction a

202 0.01 and p = 0.04, respectively) and severe pulmonary hypertension (p = 0.014 and p = 0.05, respecti

203 rial pressures versus isolated postcapillary pulmonary hypertension (P<0.05).

204 About half of SCD-related pulmonary hypertension patients have precapillary pulmon

205 In pulmonary hypertension patients, the asymptotic pressure

206 s, and special patient populations including pulmonary hypertension, pediatrics, and pregnancy.

207 stigated lung TERT in human and experimental pulmonary hypertension (PH) and its role in controlling

208 Pulmonary hypertension (PH) and right ventricular (RV) d

209 Americans develop chronic kidney disease and pulmonary hypertension (PH) at disproportionately high r

210 Pulmonary hypertension (PH) can develop secondary to IPF

211 -beta signaling is required for experimental pulmonary hypertension (PH) caused by Schistosoma exposu

212 lusive disease (PVOD) is an uncommon form of pulmonary hypertension (PH) characterized by progressive

213 Although pulmonary hypertension (PH) contributes significantly to

214 natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension (PH) diagnosed by right heart cat

215 Pulmonary hypertension (PH) exists when mean pulmonary a

216 Pulmonary hypertension (PH) frequently coexists with sev

217 emodeling is associated with the severity of pulmonary hypertension (PH) in HF.

218 approximately 92 attenuated hypoxia-induced pulmonary hypertension (PH) in mice, whereas reconstitut

219 Pulmonary hypertension (PH) in neonates, infants, childr

220 , TGF-beta blockade can prevent experimental pulmonary hypertension (PH) in pre-clinical models.

221 and increased susceptibility to experimental pulmonary hypertension (PH) in rats, but these effects w

222 Through ventricular interdependence, pulmonary hypertension (PH) induces left ventricular (LV

223 Through ventricular interdependence, pulmonary hypertension (PH) induces left ventricular (LV

224 Pulmonary hypertension (PH) is a common and morbid compl

225 Pulmonary hypertension (PH) is a complex disorder, spann

226 RATIONALE: Pediatric pulmonary hypertension (PH) is a heterogeneous condition

227 Pulmonary hypertension (PH) is an established complicati

228 Pulmonary hypertension (PH) is associated with increased

229 Pulmonary hypertension (PH) is associated with poor outc

230 Pulmonary hypertension (PH) is associated with poor outc

231 Pulmonary hypertension (PH) is characterized by a progre

232 Pulmonary hypertension (PH) is characterized by pulmonar

233 Pulmonary hypertension (PH) is common and may result fro

234 Severe pulmonary hypertension (PH) is considered to negatively

235 Pulmonary hypertension (PH) is diagnosed by a mean pulmo

236 Pulmonary hypertension (PH) is hemodynamically classifie

237 Pulmonary hypertension (PH) is increasingly recognized a

238 ated with survival in this group and whether pulmonary hypertension (PH) reversal can influence LDL-C

239 An emerging metabolic theory of pulmonary hypertension (PH) suggests that cellular and m

240 t and mouse models of SU5416/hypoxia-induced pulmonary hypertension (PH) were used.

241 nd to be of clinical value for assessment of pulmonary hypertension (PH) with studies to date exclusi

242 Failure of this transition leads to pulmonary hypertension (PH), a major cause of newborn mo

243 scular wall cells, including fibroblasts, in pulmonary hypertension (PH).

244 ft heart disease is the most common cause of pulmonary hypertension (PH).

245 ylcholinesterase inhibition, in experimental pulmonary hypertension (PH).

246 ness and cellular metabolism occurs early in pulmonary hypertension (PH).

247 KCNK3 function could alleviate experimental pulmonary hypertension (PH).

248 pulmonary macrophages in the pathogenesis of pulmonary hypertension (PH).

249 and nodal ligands to attenuate experimental pulmonary hypertension (PH).

250 nd therapeutic implications to patients with pulmonary hypertension (PH).

251 cise tolerance is decreased in patients with pulmonary hypertension (PH).

252 x) is an established treatment for end-stage pulmonary hypertension (PH).

253 P/TAZ co-transcription factors, in promoting pulmonary hypertension (PH).

254 ation (TR) is a risk factor for mortality in pulmonary hypertension (PH).

255 udinal follow-up of children and adults with pulmonary hypertension (PH).

256 RA size is prognostic of adverse outcomes in pulmonary hypertension (PH).

257 Pulmonary hypertension (PHT) is associated with high mor

258 g patients with CDH and its association with pulmonary hypertension (pHTN) and mortality.

259 ifically define clinically relevant residual pulmonary hypertension post-PEA.

260 A 22-year-old woman with primary pulmonary hypertension presented with displacement of st

261 Present estimates suggest a pulmonary hypertension prevalence of about 1% of the glo

262 CD-associated end-organ damage (nephropathy, pulmonary hypertension, pulmonary inflammation, liver fu

263 tracardiac repair, systemic right ventricle, pulmonary hypertension, pulmonary regurgitation, pulmona

264 er or cancer therapy-associated systemic and pulmonary hypertension, QT prolongation, arrhythmias, pe

265 rt of consecutive patients with precapillary pulmonary hypertension referred between 2002 and 2011.

266 ced, or heritable PAH enrolled in the French pulmonary hypertension registry between 2006 and 2016 wh

267 by mitomycin-C (MMC) therapy from the French Pulmonary Hypertension Registry.

268 Hypertension (COMPERA), an ongoing European pulmonary hypertension registry.

269 ypertension Identified at a Referral Centre) pulmonary hypertension registry.

270 , peripheral arterial disease, hypertension, pulmonary hypertension, renal or liver disease, New York

271 95% of patients with or without preoperative pulmonary hypertension, respectively, were asymptomatic

272 Chronic thromboembolic pulmonary hypertension results from incomplete resolutio

273 Female Smad1(+/-) mice developed pulmonary hypertension (reversed by ovariectomy).

274 e inoperable and have chronic thromboembolic pulmonary hypertension, riociguat, a stimulator of solub

275 The remainder have postcapillary pulmonary hypertension secondary to left ventricular dys

276 ived steroids or nitric oxide and to develop pulmonary hypertension, seizures, encephalitis, and pneu

277 Our findings suggest IUGR-induced pulmonary hypertension should be further investigated an

278 Pulmonary hypertension subsequent to an infectious disea

279 l hypertension-targeted drugs, postoperative pulmonary hypertension, surgical complications, and addi

280 For patients with chronic thromboembolic pulmonary hypertension, surgical pulmonary endarterectom

281 , which develops pulmonary vasculopathy with pulmonary hypertension that is exacerbated by SU5416.

282 hypoxia, as evidenced by exaggerated hypoxic pulmonary hypertension that is reversed by subsequent ir

283 ertension and identifies a level of residual pulmonary hypertension that may guide the long-term mana

284 In pulmonary hypertension, the right ventricle adapts to th

285 In pulmonary hypertension, the status of the right ventricl

286 PH-LHD patients from isolated postcapillary pulmonary hypertension to Cpc-PH, which is characterized

287 mice similarly treated, which do not develop pulmonary hypertension under these circumstances.

288 ation, 63 years +/- 17) with newly diagnosed pulmonary hypertension underwent cardiac magnetic resona

289 ding those with congestive heart failure and pulmonary hypertension) used the SA-6MWTapp independentl

290 Pulmonary hypertension was common in obstructive hypertr

291 mutants demonstrated that the development of pulmonary hypertension was dependent on HIF-2alpha but n

292 fect of pulmonary arterial denervation acute pulmonary hypertension was induced in 8 pigs by intraven

293 Interestingly, pulmonary hypertension was present in 13 patients at bas

294 vious mouse model of Pneumocystis-associated pulmonary hypertension, we found that vascular remodelin

295 013, 529 consecutive children with confirmed pulmonary hypertension were enrolled in an international

296 udy, 20 patients with chronic thromboembolic pulmonary hypertension were examined at 1.5 T with a dyn

297 newly diagnosed with chronic thromboembolic pulmonary hypertension were prospectively included over

298 for diagnosis and management of SCD-related pulmonary hypertension were published recently by the Am

299 ll as lung organ cultures from patients with pulmonary hypertension were used to assess elafin-mediat

300 s in a subset of patients with postoperative pulmonary hypertension who had cardiac surgery; however,

301 nary hypertension patients have precapillary pulmonary hypertension with potential etiologies of (1)